In pre-clinical models utilizing BALB/c mice with triple-negative breast tumors, single-dose SBRT with 12 Gy delivered in 1 fraction has been shown to enrich tumor-specific T cells and CD8+ memory cytotoxic T-cells with ablative doses, as well as to enhance the therapeutic capacity and tumor control using an immune checkpoint blockade in these models [17]. The gene discussed is CD8A; the disease is neoplasm.